Form D · Biotechnology
Acer Therapeutics Inc.
Newton, MA · CIK 0001069308
Offering snapshot reported Dec 5, 2022 · SEC filing
- Reported sold
- $1.5M Offering amount: $1.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 29, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 5, 2022 | Initial | $1,499,999 | No comparison | 2 | SEC filing |
| Jul 29, 2020 | Initial | $857,493 | No comparison | 5 | SEC filing |
| Feb 19, 2013 | Initial | $650,000 | No comparison | 5 | SEC filing |
| Feb 19, 2013 | Initial | $0 | No comparison | 21 | SEC filing |
| Nov 19, 2012 | Initial | Yet to sell | No comparison | 1 | SEC filing |
| Jul 27, 2012 | Initial | $4,085,000 | No comparison | 21 | SEC filing |
| Apr 27, 2009 | Initial | $1,101,000 | No comparison | Not reported | SEC filing |
| Aug 22, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 6, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 19, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 7, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-466490
Source: Form D, filed Dec 5, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
The linked fund shows its most recently reported ADV details.
Matched by reported Form D file number
FORT WASHINGTON PRIVATE EQUITY INVESTORS XI-B, L.P.
Investment adviser: FORT WASHINGTON INVESTMENT ADVISORS INC
- Gross asset value
- $46.7M
- Beneficial owners
- 2
- ADV minimum commitment
- $0
Reported in Form ADV on Jun 23, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.
Service providers
Provider details
- Annual audit
- Yes
- Prime brokers
- No
- Custodians
- Yes
- Administrator other than the adviser
- No
- External marketing
- No
ERNST & YOUNG, LLP
PCAOB 42
Filing source
Form ADV 2113237 · Jun 23, 2026 · Schedule D 7.B.(1), fund 805-3357812055
Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jason Amello | Director |
| Stephen Aselage | Director |
| Jefferson E. Davis | Executive |
| John M Dunn | Director |
| Michelle Griffin | Director |
| Tanya Hayden | Executive |
| David Hung | Director |
| David E. Jorden | Director, Executive |
| Donald R. Joseph | Executive |
| John M. Klopp | Executive |
| Gail J. Maderis | Director |
| David B. Mc Williams | Director |
| Harry S. Palmin | Executive |
| Bernie Paul | Executive |
| Adrian Quartel | Executive |
| Michael S. Richman | Director |
| Donna R. Rill | Executive |
| Chris Schelling | Director, Executive |
| Scott B. Seaman | Director |
| Matthew T. Seibt | Executive |
| Jaye L. Thompson | Executive |
| Neil K. Warma | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:Newton, MA, 02458